Shares of BioAge (NASDAQ:BIOA) cratered 70% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns.

The study had been evaluating azelaprag as both a monotherapy and